RNAi Roundtable: HTT02 - ALNYLAM PHARMACEUTICALS INC

Explicit Guidance:

• No explicit financial guidance (revenue, earnings, margins, capex) provided for any future period.
• Pivotal Trial Initiation: Plan to initiate a placebo-controlled pivotal study in 2027, pending regulatory alignment.
• Dosing Strategy: Aim to explore biannual (every 6 months) dosing regimens to achieve deep and durable knockdown, based on modeling of non-human primate data.

Business-Segment Outlook:

• Huntington's Disease (Brezosiran/ALN-HHT02):
  • Target Engagement: Initial Phase 1b data showed a mean reduction of 60–64% in CSF mutant huntingtin at month 3, with individual reductions up to 83%.
  • Safety Profile: No observed dose-dependent increases in CSF neurofilament light (NFL), CNS inflammatory markers (protein/white blood cells), or ventricular volume changes.
  • Next Steps: Ongoing Phase 1b open-label extension (OLE) will continue with patients dosed every 6 months to assess long-term safety and explore efficacy trends.
• CNS Pipeline Expansion: Leveraging the C16s RNA delivery platform to target the Central Nervous System (CNS), with a growing pipeline of investigational CNS-targeted RNAi therapeutics.
• Collaborations: Building a pipeline in collaboration with Regeneron covering Alzheimer's disease, Huntington's disease, ALS, and Parkinson's disease.

Market and Competitive Outlook:

• Target Differentiation: Brezosiran employs an exon 1 targeting strategy designed to lower both full-length mutant huntingtin and the shorter HTT1A isoform, addressing limitations of prior candidates that only targeted full-length mutant protein.
• Patient Population: Estimates ~100,000 symptomatic patients globally (including ~33,000 in the U.S.), with an additional >100,000 gene carriers in the U.S. who are currently undiagnosed or pre-symptomatic.
• Diagnosis Rates: Anticipate an increase in patient identification and diagnosis rates as effective therapies are developed, moving beyond the current "low diagnosis rate" (~33% of carriers diagnosed).
• Clinical Endpoints: Pivotal trials are expected to utilize commonly accepted clinical endpoints (e.g., UHDRS, TFC) over 24–36 month durations to account for disease progression rates.

Macro / Industry Outlook:

• Regulatory Strategy: Pursuing a parallel path of an OLE for long-term safety/exploratory data and a definitive placebo-controlled pivotal study; regulatory approval paths (including potential accelerated approval) remain dependent on the totality of data and health authority discussions.
• Administration Route: Acknowledges intrathecal (IT) delivery as the current standard for Brezosiran; no immediate plan to switch to systemic "shuttle" approaches for this specific program, though actively developing CNS shuttle platforms for the broader portfolio to optimize future delivery.
• Payer/Provider Landscape: Confidence that the unmet need and high efficacy potential will drive patient identification and treatment acceptance among specialists and payers.

Strategic Initiatives:

• Clinical Development: Advancing Brezosiran in two parallel tracks: (1) Ongoing Phase 1b OLE for sustained safety/efficacy data; (2) Preparation for 2027 pivotal trial.
• Platform Extension: Expanding the C16s RNA delivery platform to treat serious neurodegenerative diseases where RNAi can have meaningful impact.
• Strategic Alignment: Brezosiran advances progress toward Alnylam 2030 goals of delivering transformative medicines beyond approved products.

Risks and Headwinds to Outlook:

• Timing of Efficacy Data: Acknowledges that meaningful efficacy signals from the OLE may require 24–36 months to distinguish from natural history progression.
• Regulatory Uncertainty: Pivotal trial timing and design remain pending final regulatory alignment and discussions.
• Measurement Challenges: Difficulty in directly measuring HTT1A reduction in CSF due to low abundance and aggregation; reliance on full-length huntingtin knockdown as a surrogate.
• Safety unknowns: While preclinical primate data shows tolerance to >90% wild-type lowering, the safety of deep wild-type lowering in humans over extended periods remains a key area of monitoring.
• Therapeutic Window: Uncertainty regarding the ideal time of intervention (early vs. later stage) to maximize benefit, though preclinical data suggests earlier is better.

Management Tone on the Future:

• Confidence: High confidence in the C16s platform and the exon 1 targeting strategy, citing "encouraging" and "robust" Phase 1b results.
• Urgency: Explicit commitment to "move with urgency" given the devastating nature of Huntington's disease and the lack of current disease-modifying therapies.
• Differentiation: Strong belief that targeting HTT1A is critical for efficacy, distinguishing their approach from competitors (e.g., Biogen/Regeneron ASOs) that showed safety signals or limited efficacy by missing this isoform.
• Caveats: Management emphasizes that current data establishes safety and target engagement, not clinical efficacy, and stresses the need for long-term studies to confirm disease modification.

Miscellaneous:

• Competitor Context: References prior ASO programs (e.g., Tominersen, WVE003) that observed increases in NFL (neuroaxonal injury biomarker) despite moderate knockdown; contrasts this with Brezosiran's lack of NFL elevation.
• Commercial Viability: Expects a "sizable commercial opportunity" driven by the large undiagnosed carrier population and the potential for a transformative therapy.